|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2004-11-9
|
|
pubmed:abstractText |
In patients with advanced Parkinson disease (PD) who are undergoing long-term treatment with a dopaminergic medication, a down-regulation of striatal dopamine D2 receptor expression has been demonstrated and interpreted as a consequence of either the disease itself or dopaminergic drug administration.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0003-9942
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
61
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1705-9
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15534182-Aged,
pubmed-meshheading:15534182-Disease Progression,
pubmed-meshheading:15534182-Dopamine Agents,
pubmed-meshheading:15534182-Dopamine Antagonists,
pubmed-meshheading:15534182-Down-Regulation,
pubmed-meshheading:15534182-Electric Stimulation Therapy,
pubmed-meshheading:15534182-Female,
pubmed-meshheading:15534182-Humans,
pubmed-meshheading:15534182-Ligands,
pubmed-meshheading:15534182-Male,
pubmed-meshheading:15534182-Middle Aged,
pubmed-meshheading:15534182-Parkinson Disease,
pubmed-meshheading:15534182-Positron-Emission Tomography,
pubmed-meshheading:15534182-Raclopride,
pubmed-meshheading:15534182-Receptors, Dopamine D2,
pubmed-meshheading:15534182-Subthalamic Nucleus
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study.
|
|
pubmed:affiliation |
Neurological Department D, The Pierre Wertheimer Neurological Hospital and INSERM U 534, Lyon, France. S.Thobois@ion.ucl.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study
|
